Why the study?
Effective therapies concurrently targeting both IL-17A-driven inflammation and TGF-beta-induced fibrotic remodeling in cardiac fibroblasts are lacking for myocarditis.
Does targeted delivery of MLN4924 reduce myocardial inflammation and fibrosis in a mouse model of autoimmune myocarditis?
Does targeted delivery of MLN4924 reduce myocardial inflammation and fibrosis in a mouse model of autoimmune myocarditis?
Fibroblast-targeted delivery of the neddylation inhibitor MLN4924 presents a promising precision medicine strategy to reduce inflammation and fibrosis in autoimmune myocarditis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeted MLN4924 in experimental myocarditis; leaves open translation to human autoimmune disease.
BACKGROUND: Myocarditis is a leading cause of heart failure in young individuals and may progress to dilated cardiomyopathy due to inflammation-driven cardiac fibrosis. Cardiac fibroblasts (CFs) are key contributors to this process, mediating both IL-17A-driven inflammatory responses and TGF-β-induced fibrotic remodeling. However, effective therapies that concurrently target these dual pathological pathways in CFs are lacking. METHODS: We evaluated the neddylation inhibitor MLN4924 in a mouse model of experimental autoimmune myocarditis (EAM). A fibroblast-targeted biomimetic nanoparticle (FMlipo@MLN4924) was engineered and its delivery efficiency and therapeutic effects were assessed in vitro and in vivo. RESULTS: Systemic MLN4924 treatment significantly alleviated myocardial inflammation, reduced cardiac fibrosis by approximately 50% and preserved cardiac function in EAM mice. Mechanistically, MLN4924 dually suppressed IL-17A-induced chemokine production and TGF-β-driven fibrotic activation in CFs. The FMlipo@MLN4924 system demonstrated more than a 2.5-fold increase in cardiac accumulation compared to non-targeted liposomes. This targeted delivery resulted in superior therapeutic efficacy, achieving enhanced suppression of immune infiltration and fibrotic remodeling with no observable toxicity. CONCLUSION: MLN4924 exerts dual anti-inflammatory and anti-fibrotic effects in autoimmune myocarditis by regulating IL-17A and TGF-β pathways in CFs. Fibroblast-membrane camouflaging enhances MLN4924 delivery and performance, presenting a promising precision medicine strategy for immune-mediated cardiac injury with clear translational potential.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: